In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 361 to 370 of 437

TitleTypeExpected publication date
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]Technology appraisal guidance
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]Technology appraisal guidance
Neonatal infection: antibiotics for prevention and treatment - updateNICE guideline
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]Technology appraisal guidance
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]Technology appraisal guidance
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Technology appraisal guidance
Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value AssessmentHealth technology evaluation
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All